---
id: ai-trial-operations
name: AI for clinical trial operations
aliases:
  - AI trial operations
  - AI patient matching
  - trial recruitment AI
  - clinical trial automation
substrate_family: B
substrate_tags:
  - B.4
enabled_by: "NLP over unstructured clinical notes, LLMs for document generation, and marketplaces or networks that connect sponsors to sites and patients"
mechanism: "AI reads clinical records and trial protocols to match patients, select sites, drive recruitment, and automate regulatory and safety documents"
new_capability: "automate the operational bottlenecks of running a trial: finding the right patients and sites and producing the paperwork"
what_it_could_unlock: "trials that recruit faster and cost less by removing manual matching, feasibility, and document work"
capabilities:
  - capability: "AI patient matching and site or feasibility selection"
    what_it_could_unlock: "faster enrolment and better-chosen sites by surfacing eligible patients from messy records"
    mechanism: "NLP parses structured and unstructured EHR data against protocol eligibility criteria in near real time"
    technology_readiness_level: 8
    translational_gap: "matching quality depends on EHR access and data quality, and site or clinician workflow adoption is slow"
    closest_companies:
      - Deep 6 AI
      - Inato
  - capability: "regulatory and safety document automation"
    what_it_could_unlock: "faster submissions and pharmacovigilance by drafting and structuring trial and safety documents"
    mechanism: "LLMs generate and structure protocols, submissions, and adverse-event narratives from source data"
    technology_readiness_level: 7
    translational_gap: "regulated documents need human review and validation, so autonomy is capped by liability and audit needs"
related_primitives:
  - multimodal-clinical-data-platform
  - biosimulation-qsp
use_cases:
  - patient identification and pre-screening for enrolment
  - site selection and trial feasibility forecasting
  - recruitment and decentralised or direct-to-patient enrolment
  - regulatory submission and pharmacovigilance document drafting
technology_readiness_level: 8
evidence_level: real_world_proven
translational_gap: "the tools are deployed in real trials, but value depends on EHR access, data quality, and slow site and sponsor workflow adoption, and regulated document generation still needs human sign-off"
what_needs_to_happen: "broader EHR interoperability, proof of enrolment and cost gains at scale, and validated human-in-the-loop autonomy for regulated documents"
closest_companies:
  - Deep 6 AI
  - Inato
  - Lindus Health
  - Paradigm
  - Lokavant
  - ArisGlobal
  - Yseop
closest_labs:
  - academic clinical-informatics and trial-methodology groups
commercialisation_status: commercial_scaled
regulatory_complexity: medium
capex_intensity: low
defensibility: medium
notes: "Deep 6 AI and Inato lead matching and site marketplaces; Lindus Health (raised $55M Series B, Jan 2025) runs an AI-native CRO model; ArisGlobal and Yseop focus on safety and regulatory document automation. Value is real but gated by EHR access and workflow adoption."
scan:
  bucket: emerging
  paper_cagr_pct: null
  mean_fwci: 9.15
  industry_share: 0.069
  patent_total: 1
  patent_cagr_pct: null
  company_share: 1.0
  as_of: '2026-07-07'
last_verified: "2026-07-07"
---

## Mechanism

AI trial operations applies language models to the workflow of running a trial rather than to the science of the drug. Natural-language processing reads structured and unstructured clinical records and matches them against protocol eligibility criteria to surface candidate patients and to forecast which sites can realistically enrol. Large language models then draft and structure the heavy paperwork: protocols, regulatory submissions, and adverse-event narratives for pharmacovigilance.

## What it unlocks

Faster, cheaper trial execution. Patient matching pulls eligible people out of messy EHR data that manual screening misses; site and feasibility tools pick locations that will actually recruit; document automation compresses the submission and safety-reporting burden. Marketplace models (Inato) widen the site pool to community clinics, and AI-native CRO models (Lindus Health) rebuild the whole operational stack around these tools. The net effect is shorter enrolment timelines, the single biggest cause of trial delay.

## Translational gap

The honest TRL is 8: these tools are in production in real trials, so the primitive is real-world proven. The block to fuller value is not model quality but access and adoption. Matching depends on EHR interoperability and data quality that vary widely, and site or clinician workflows change slowly. Regulated document generation is capped by liability and audit requirements, so it stays human-in-the-loop rather than autonomous. Progress needs broader EHR access, hard evidence of enrolment and cost gains at scale, and validated human-in-the-loop autonomy for regulated documents.

## Notes

Defensibility is medium: the models are increasingly commoditised, so the moat is EHR access, site or patient network effects, and workflow lock-in rather than the AI itself. Sits directly on `multimodal-clinical-data-platform` for its data and complements `biosimulation-qsp`, which optimises trial design while this optimises trial execution.
